Sign in Pull a receipt

BBIO

BridgeBio Pharma, Inc.

Biotechnology · Biotechnology

$251.07 sample

-0.68 (-0.27%) 1D

Market cap

$593.8B

Price as of

2026-10-29

Latest filing

8-K · 2026-10-16

Alerts

8

Price$251.07 +0.30% 3M daily closessample

264.84243.84

2026-08-032026-08-252026-09-162026-10-072026-10-29

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 27INSInsider sell: Chief Executive Officer
Oct 16SEC8-K filed: material event
Oct 07SEC10-Q filed
Sep 30INSInsider sell: EVP, Operations
Sep 25INSInsider sell: General Counsel
Sep 22INSInsider buy: 10% owner
Sep 11INSInsider sell: Chief Financial Officer
Sep 02INSInsider buy: General Counsel

Sign up to see the real BBIO record →

Company facts

SEC EDGAR registration

Name: BridgeBio Pharma, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: -30sample, -100 to +100
Reporting currency: USD

Who is positioning in BBIO

sample

Insiders: 13 insider transactions over 90 days, net selling, $759.1M
Congress: 2 members traded over 90 days
Institutions · 13F: 37 funds hold $3.4B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$31.7B +18.5% y/y

Q4 2024Q3 2026

Inventory$19.1B +18.8% y/y

Q4 2024Q3 2026

Accounts receivable$14.0B +8.2% y/y

Q4 2024Q3 2026

Total debt$37.0B +10.3% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $191.0B +5.1% 3M
Sample peer B: $102.6B -11.6% 3M
Sample peer C: $474.1B -5.4% 3M
Sample peer D: $332.8B +14.3% 3M
Sample peer E: $194.1B +12.9% 3M